Q4 2025 earnings call: gedatolisib NDA priority review, VIKTORIA-1 data and launch plans ahead of July 2026 PDUFA—read now.
Celcuity (NASDAQ:CELC) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight progress ...
The U.S. Food and Drug Administration (“FDA”) accepted Celcuity’s New Drug Application (“NDA”) and granted Priority Review with a Prescription ...
Celcuity LLC reports fourth-quarter earnings Wednesday after market close, as the clinical-stage biotechnology company ...
Celcuity Inc. ( CELC) Q4 2025 Earnings Call March 25, 2026 4:30 PM EDT Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2025 Financial Call. [Operator ...
A replay of the webcast will be available on the Celcuity website following the live event. Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the ...
(RTTNews) - Shares of Celcuity Inc. (CELC) touched an all-time high of $53.85 in early trading today, building on several eventful months driven by developments surrounding its lead drug candidate, ...
Investigators sought to determine whether adding gedatolisib to fulvestrant, with or without palbociclib, improved clinical outcomes in patients with HR-positive/HER2-negative/PIK3CA wild-type ...
Celcuity highlighted strong phase III second-line data for gedatolisib in PIK3CA "wild-type" HR-positive breast cancer — the ...
Celcuity (CELC) announced overall survival, OS, data from two patient cohorts evaluated in a Phase 1b trial with gedatolisib, a pan-PI3K/mTORC1/2 inhibitor, in combination with palbociclib and either ...
As previously presented, gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and gedatolisib + fulvestrant (“gedatolisib doublet”) reduced the risk of disease progression or death versus ...
Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers This phase III randomized trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results